A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2017
Price : $35 *
At a glance
- Drugs LHW 090 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals Corporation
- 31 Aug 2018 Biomarkers information updated
- 27 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.